Generic Name and Formulations:
Alfuzosin (as HCl) 10mg; ext-rel tabs.
Covis Pharmaceuticals, Inc.
Indications for UROXATRAL:
Benign prostatic hyperplasia (BPH).
Limitations Of use:
Not for use in children or for the treatment of hypertension.
Swallow whole. Take immediately after same meal each day. 10mg once daily.
Concomitant potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir). Moderate or severe hepatic insufficiency.
Not for use in women. Discontinue if angina develops or worsens. Severe renal insufficiency (CrCl <30mL/min). Hypotension. Mild hepatic impairment. History of QT interval prolongation. Exclude prostate cancer prior to initiation. Cataract surgery (intraoperative floppy iris syndrome possible). Pregnancy (Cat.B).
See Contraindications. Do not use with other α-blockers. Increased hypotension with concomitant nitrates, PDE5 inhibitors, other antihypertensives. Potentiates and is potentiated by cimetidine. Potentiates cardiovascular effects of atenolol. Caution with drugs that prolong QT interval.
Dizziness, upper respiratory tract infection, headache, fatigue; postural hypotension, syncope; rare: priapism.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness